ArticleKidney3602026
Impact of Disease Recurrence and Outcomes following Kidney Transplantation for GN: A Prospective Nationwide Cohort Study.
Article in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
key pointsGN is one of the main causes of kidney transplantation. In patients transplanted for GN, the risk of recurrence is approximately 16%. Recurrence significantly worsens the prognostic, tripling and doubling the risk of graft loss and acute rejection, respectively. Despite having more often received immunosuppression before transplantation, patients with GN are not at increased risk of post-transplantation cancers.
backgroundPatients who receive transplants after kidney failure due to GN (GN-KTx) constitute a significant portion of recipients and may face unique challenges post-transplantation, related to the risk of GN recurrence and a higher global burden of immunosuppression.
methodsWe analyzed patient and graft outcomes, including the risk of graft loss in relation to recurrence in GN-KTx, compared with patients transplanted for other causes, using data from the prospective nationwide Swiss Transplant Cohort Study.
resultsAmong 2631 included patients, 701 were GN-KTx, with IgA nephropathy being the most common GN subtype. GN-KTx recipients were younger and more likely to receive living donor organs. During a mean follow-up period of 5.3 years (interquartile range, 2.3-8.2), the 5-year cumulative incidence of graft loss was similar across groups, with GN-KTx at 6%. Notably, GN-KTx had a similar incidence of acute rejection as other groups. Recurrence occurred in 16% of GN-KTx within a mean time of 1.7 years (interquartile range, 0.28-2). Patients with recurrence faced a three-fold higher risk of graft loss. Furthermore, disease recurrence was associated with a two-fold higher risk of acute rejection compared with nonrecurrent GN-KTx. Interestingly, regarding cancer risks, GN-KTx patients had the lowest incidence of skin cancer and no higher risk of nonskin cancers, despite greater exposure to immunosuppression compared with other kidney transplant recipients.
conclusionsThese real-life setting contemporary multicenter data highlight the importance of post-transplant monitoring for GN recurrence, given the strong association with poor graft outcomes and higher rejection rates. This is important in the context of current development of targeted therapies for GN in native kidneys that could be transposed to transplanted kidneys.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.